Melissa E. Hughes

7.1k total citations · 3 hit papers
103 papers, 3.5k citations indexed

About

Melissa E. Hughes is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Melissa E. Hughes has authored 103 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 65 papers in Cancer Research and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Melissa E. Hughes's work include Breast Cancer Treatment Studies (54 papers), HER2/EGFR in Cancer Research (28 papers) and Breast Lesions and Carcinomas (17 papers). Melissa E. Hughes is often cited by papers focused on Breast Cancer Treatment Studies (54 papers), HER2/EGFR in Cancer Research (28 papers) and Breast Lesions and Carcinomas (17 papers). Melissa E. Hughes collaborates with scholars based in United States, Australia and Canada. Melissa E. Hughes's co-authors include Jane C. Weeks, Richard L. Theriault, Stephen B. Edge, Joyce C. Niland, Rebecca A. Ottesen, Eric P. Winer, Douglas W. Blayney, Yu‐Ning Wong, Nancy U. Lin and Ann H. Partridge and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Melissa E. Hughes

88 papers receiving 3.4k citations

Hit Papers

Clinicopathologic features, patterns of recurrence, and s... 2012 2026 2016 2021 2012 2022 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
    2012 475 citations Nancy U. Lin, Melissa E. Hughes et al. Cancer profile →
  2. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
    2022 163 citations Sheheryar Kabraji, Melissa E. Hughes et al. Nature Communications profile →
  3. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
    2022 147 citations Paolo Tarantino, Qingchun Jin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melissa E. Hughes United States 30 2.2k 2.0k 758 536 462 103 3.5k
S. Kyriakides Italy 8 2.1k 0.9× 2.0k 1.0× 795 1.0× 572 1.1× 526 1.1× 13 3.6k
Günther Gruber Switzerland 15 1.7k 0.8× 1.8k 0.9× 556 0.7× 596 1.1× 513 1.1× 24 3.2k
Barry C. Lembersky United States 31 2.5k 1.1× 1.1k 0.5× 764 1.0× 555 1.0× 276 0.6× 82 3.3k
Dirk Arnold Germany 17 2.9k 1.3× 1.1k 0.5× 921 1.2× 602 1.1× 859 1.9× 108 4.1k
Yasuaki Sagara Japan 25 1.8k 0.8× 1.2k 0.6× 656 0.9× 383 0.7× 422 0.9× 109 2.9k
Elisa Port United States 27 1.4k 0.6× 2.0k 1.0× 385 0.5× 1.1k 2.0× 401 0.9× 74 3.1k
Deborah Collyar United States 22 1.7k 0.8× 1.7k 0.9× 530 0.7× 442 0.8× 477 1.0× 69 3.2k
Stefan Paepke Germany 24 1.4k 0.6× 1.6k 0.8× 460 0.6× 585 1.1× 268 0.6× 144 2.8k
M. Castiglione Switzerland 26 2.8k 1.2× 2.5k 1.3× 835 1.1× 786 1.5× 715 1.5× 48 5.0k
T. Delozier France 30 3.3k 1.5× 1.7k 0.8× 987 1.3× 277 0.5× 568 1.2× 92 4.3k

Countries citing papers authored by Melissa E. Hughes

Since Specialization
Citations

This map shows the geographic impact of Melissa E. Hughes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa E. Hughes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa E. Hughes more than expected).

Fields of papers citing papers by Melissa E. Hughes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa E. Hughes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa E. Hughes. The network helps show where Melissa E. Hughes may publish in the future.

Co-authorship network of co-authors of Melissa E. Hughes

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa E. Hughes. A scholar is included among the top collaborators of Melissa E. Hughes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa E. Hughes. Melissa E. Hughes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goel, Shom, Bojana Jovanović, Melissa E. Hughes, et al.. (2025). A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 31(8). 1427–1436. 3 indexed citations
2.
3.
Martin, Alyssa R., Melissa E. Hughes, Gregory J. Kirkner, et al.. (2025). Patterns of presentation, treatment, and survival among older adults with metastatic breast cancer: Results from a large prospective registry. Journal of Geriatric Oncology. 16(5). 102261–102261.
4.
5.
Raghavendra, Akshara Singareeka, Qingchun Jin, Melissa Grimm, et al.. (2024). Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆. ESMO Open. 9(11). 103973–103973. 4 indexed citations
6.
7.
Grinshpun, Albert, Wen Ma, Giorgio Gaglia, et al.. (2024). Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. npj Breast Cancer. 10(1). 42–42. 3 indexed citations
8.
Tarantino, Paolo, Noah Graham, Melissa E. Hughes, et al.. (2024). Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. European Journal of Cancer. 201. 113920–113920. 12 indexed citations
9.
Hughes, Melissa E., Alyssa R. Martin, Janet Files, et al.. (2024). Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. Neuro-Oncology. 27(1). 184–194. 4 indexed citations
10.
Jovanović, Bojana, S. Church, Khrystyna North, et al.. (2024). Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies. Clinical Cancer Research. 30(20). 4768–4779. 3 indexed citations
11.
Rosenberg, Shoshana M., Elizabeth Riley, Melissa E. Hughes, et al.. (2024). Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer. Breast Cancer Research and Treatment. 209(3). 513–520. 1 indexed citations
12.
Taifour, Tarek, Tung Bui, Dongmei Zuo, et al.. (2024). Osteopontin is a therapeutic target that drives breast cancer recurrence. Nature Communications. 15(1). 9174–9174. 17 indexed citations
13.
Gupta, Hersh, Rachel A. Freedman, Melissa E. Hughes, et al.. (2023). Abstract P5-14-06: Tumor Genomic Landscape in Older Women with Metastatic Breast Cancer (MBC). Cancer Research. 83(5_Supplement). P5–14.
14.
Laws, Alison, Mirelle Lagendijk, Melissa E. Hughes, et al.. (2023). Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors. Annals of Surgical Oncology. 31(3). 1623–1633. 8 indexed citations
15.
Coller, Beth-Ann, William Lapps, Samantha Bruno, et al.. (2022). Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines. Vaccines. 10(9). 1446–1446. 6 indexed citations
16.
Tarantino, Paolo, Qingchun Jin, Rinath Jeselsohn, et al.. (2022). 1MO Prognostic and biologic significance of HER2-low expression in early breast cancer. Annals of Oncology. 33. S124–S124. 5 indexed citations
17.
Vaz-Luís, Inês, Melissa E. Hughes, Angel M. Cronin, et al.. (2015). Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study. Cancer. 121(12). 1937–1948. 6 indexed citations
18.
19.
20.
Wong, Yu‐Ning, Rebecca A. Ottesen, Melissa E. Hughes, et al.. (2011). Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?. The Oncologist. 16(5). 559–565. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Kyriakides Breakdown of academic impact, for papers by Günther Gruber Breakdown of academic impact, for papers by Barry C. Lembersky Breakdown of academic impact, for papers by Dirk Arnold Breakdown of academic impact, for papers by Yasuaki Sagara Breakdown of academic impact, for papers by Elisa Port Breakdown of academic impact, for papers by Deborah Collyar Breakdown of academic impact, for papers by Stefan Paepke Breakdown of academic impact, for papers by M. Castiglione Breakdown of academic impact, for papers by T. Delozier
Rankless by CCL
2026